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Aggregation of amyloidogenic proteins is an abnormal biological process 
implicated in neurodegenerative disorders. While the aggregation process of 
amyloid-forming proteins has been studied extensively, the mechanism of 
aggregate removal is poorly understood. We recently demonstrated that 
proteasomes could fragment filamentous aggregates into smaller entities, 
restricting aggregate size[1]. Here, we show in vitro that UBE2W can modify the 
N-terminus of both αS and tauK18 with a single ubiquitin moiety. We demonstrate 
that an engineered N-terminal Ub modification changes the aggregation process 
of both proteins, resulting in the formation of structurally distinct aggregates. 
Single-molecule approaches further reveal that the proteasome can target 
soluble oligomers assembled from Ub-modified proteins independently of its 
peptidase activity, consistent with our recently reported fibril-fragmenting 
activity. Based on these results, we propose that proteasomes are able to target 
oligomers assembled from N-terminally ubiquitinated proteins. Our data suggest 
a possible disassembly mechanism by which N-terminal ubiquitination and the 
proteasome may together impede aggregate formation. (151 words) 
 
 
Introduction 
The 26S proteasome holoenzyme is responsible for selective protein degradation in 
eukaryotic cells[2]. Proteins selected for degradation are often covalently modified 
with ubiquitin (Ub) moieties, which are recognized by the proteasome[2]. The 
proteolytic activity required for degradation is provided by the 20S core particle (CP) 
of the holoenzyme, while the 19S regulatory particle (RP) that caps the CP on one or 
both ends is responsible for substrate recognition and ATP-dependent substrate 
unfolding and translocation into the CP[3-5]. Many biological processes are 
dependent on the proteasome through controlled degradation of key factors, including 
homeostasis, unfolded protein response and proteostasis[6]. As such, cellular 
proteasomes are responsible for degrading damaged proteins, thereby preventing the 
accumulation of misfolded and amyloidogenic proteins, which have a propensity to 
form aggregates[7]. 
Aggregation of amyloidogenic proteins progresses through several stages, 
during which protein monomers assemble into soluble aggregates (oligomers) that 
through further aggregation events eventually undergo conformational rearrangement 
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into filamentous aggregates (fibrils). The process of protein aggregation is harmful to 
normal cell physiology and is often associated with neurodegenerative disorders[8]. 
At the cellular level, accumulation of aggregates could be due to an increased rate of 
aggregation or decreased rate of aggregate removal, due to e.g. changes in the ability 
to disassemble or degrade aggregates. Aggregates assembled from amyloidogenic 
proteins tau and α-synuclein (αS) have been implicated in Alzheimer’s (AD) and 
Parkinson’s disease (PD), respectively[9,10]. Both tau and αS are intrinsically 
disordered in their non-amyloid state as monomers, and have been reported to be 
degradation-resistant as aggregates[11-14].  
The inability to process certain aggregates may be coincident with proteasome 
malfunction, which in certain brain regions of AD and PD patients have been reported 
with decreased activity[15,16]. We recently demonstrated that the mammalian 
proteasome holoenzyme possessed a fibril-fragmenting activity, reducing the size of 
large tau and αS fibrils into smaller entities in vitro[1]. Importantly, the proteasome 
catalyzed this fibril-fragmenting process in a Ub-independent manner. It is currently 
unclear how these smaller aggregate entities may be further processed by the cellular 
mechanisms. A recent study has further detailed the interactions of small soluble 
aggregated amyloidogenic proteins (oligomers) with the proteasome, which is 
markedly impaired by oligomer binding[17]. 
Studies in cells have indicated that monomeric tau and αS proteins could be 
degraded by the proteasome in a Ub-dependent manner[18-21], suggesting that 
aggregates of ubiquitinated proteins may accumulate when proteasomal functions are 
compromised. This assumption is supported by the observation of abundantly 
monoubiquitinated tau fibrils isolated from AD patient brain samples[22]. In addition, 
αS in the PD-associated Lewy Bodies is also mainly monoubiquitinated[16,23]. Both 
tau and αS have dedicated Ub ligases, AXOT/MARCH7[24] and SIAH1[25,26], 
respectively, which preferentially monoubiquitinate their substrates. UBE2W, a Ub-
conjugating enzyme that directly monoubiquitinates the N-terminus of intrinsically 
disordered proteins[27], has also been shown to modify tau[22,23]. Such N-terminal 
monoubiquitination is a well-defined degron recognized by the Ub-fusion degradation 
(UFD) pathway, which has been found in both yeast[28] and mammalian 
systems[29,30] to target misfolded proteins for proteasomal degradation and prevent 
cell stress. It is plausible to further hypothesize that aggregates assembled from N-
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terminal Ub-modified proteins would also recruit proteasomes for processing through 
the UFD pathway. 
Here we show that the mammalian proteasome holoenzyme can target 
oligomers assembled from ubiquitinated tau aggregation domain (tauK18) and αS. We 
found that both tauK18 and αS may become ubiquitinated on the N-terminus by 
UBE2W. Using genetically engineered proteins with an N-terminal Ub moiety on 
tauK18 and αS, we demonstrated that such Ub modification delayed the aggregation 
process, which resulted in distinct aggregate structures compared to their unmodified 
counterparts. In addition, proteasomal functions were maintained in the presence of 
these Ub-modified aggregates. This was supported by data from single-molecule 
fluorescence spectroscopy experiments, which found a reduction in the number and 
the size of oligomers following proteasome treatment. The ability to target oligomers 
was not affected by Velcade-mediated inhibition of proteasomal proteolytic activity, 
suggesting that oligomer disassembly is not dependent on degradation. Based on these 
observations, we propose that N-terminal Ub modification on tau and αS enables 
proteasomes to target and remove oligomers assembled from these modified proteins.  
 
Results 
N-terminal Ub modification on αS and tauK18 delays protein aggregation 
We chose to use full-length αS and a tetra-repeat domain of tau (tauK18) as model 
amyloidogenic proteins since both protein constructs have a similar molecular weight 
(~14 kDa, Figure 1a). Using established protocols to purify untagged recombinant 
proteins of wild-type αS and tauK18 fragment, we found that both proteins could be 
ubiquitinated by UBE2W (Figure 1b). The reaction did not continue beyond 
monoubiquitination as UBE2W specifically recognizes disordered sequences at the N-
terminus of the substrate.  
Protein ubiquitination by UBE2W did not reach completion after 2 hrs, 
resulting in a two-component mixture of Ub-modified and unmodified protein. To 
obtain homogenous and pure Ub-modified αS and tauK18, we genetically engineered 
constructs that expressed fusion proteins with a single Ub moiety immediately before 
the first residue of αS or tauK18 (Ub-αS and Ub-tauK18, SFigure 1). These engineered 
N-terminal Ub fusion proteins were protected from deubiquitination by a Gly76Ser 
substitution of the C-terminal residue of Ub. We further separately cloned the 
sequences of αS and tauK18 alone and purified these unmodified recombinant proteins 
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 5 
using the same procedure as for the engineered Ub-modified proteins for consistency 
(see Materials and Methods).  
Ub-αS and Ub-tauK18 were allowed to aggregate under identical conditions as 
their unmodified counterparts and measured by ThT, which bound to E-sheet rich 
amyloid structures. Unmodified αS entered an exponential phase reaching a half-
saturated ThT intensity (thalf) at ~11 hrs (Figure 1c). In contrast, the aggregation of 
Ub-αS showed an extended lag phase, and reached half-saturation with a delay of 14 
hrs (thalf =25 hrs). This Ub-dependent delay was even more apparent for Ub-tauK18 
(estimated thalf of 96 hrs), whose aggregation was delayed by ~38 hrs compared to 
tauK18 (thalf =58 hrs, Figure 1d). These results suggest that Ub modification might 
decrease the rate of aggregate formation and/or the level of total amyloid aggregates 
under our reaction conditions.  
 Aggregates assembled beyond 96 hrs were further imaged under TEM to 
qualitatively compare the effect of Ub modification. Interestingly, while fibrils were 
detected from unmodified αS, those formed from Ub-αS mostly appeared as small 
amorphous assemblies (Figure 2a). Despite repeated attempts, we could not detect 
any filamentous aggregates from Ub-αS under TEM. In comparison, Ub-modified 
tauK18 assembled into aggregates that appeared thinner and less filamentous-like than 
unmodified tauK18, which were detected abundantly (Figure 2b). These results 
indicate that the morphology of filamentous aggregates is affected by N-terminal Ub 
modification.  
 
Single-molecule measurements of Ub-modified aggregates 
We previously established single-molecule fluorescence methods to measure the 
aggregation process independently of aggregate structure and to estimate the 
proportion of soluble aggregates (oligomers)[31-33]. In this study, we applied the 
same method and labeling strategy to attach fluorescent dyes to αS and tauK18 
(SFigure 2a). Using this approach, we mixed the same protein labeled with Alexa488 
or Alexa647 in a 1:1 molar ratio and initiated the aggregation reaction. Aggregate 
samples were flowed through a microfluidic channel and excited at suitable 
wavelengths with two overlapping lasers using a confocal microscope (SFigure 2b). 
Oligomers (here defined as 2-150mers) formed during aggregation will contain both 
dyes and give rise to coincident fluorescent bursts when they pass through the 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 6 
confocal volume of the laser (Two Color Coincidence Detection (TCCD))[33], while 
any monomer signal will not give rise to coincident fluorescent bursts (Figure 3a). 
The fraction of all fluorescence bursts that are coincident is proportional to the 
fraction of oligomers present and is measured by the association quotient Q (see 
Materials and Methods).  
We could reproducibly detect oligomers from both tauK18 and Ub-tauK18 early 
in the aggregation process (Figure 3b). The presence of tauK18 oligomers remained 
steady within the first 24 hrs, qualitatively consistent with our previously published 
results[32]. In comparison, Ub-tauK18 oligomers could be detected at a steady level up 
to 48 hrs from the start of aggregation reaction. An apparent reduction of the fraction 
of soluble oligomers with time was detected in both unmodified and Ub-modified 
tauK18 beyond 50 and 70 hrs, respectively. The loss of soluble oligomers as 
aggregation progresses had previously also been observed for tauK18 without Ub 
modification[32], and is likely due to presence of aggregates that are either insoluble 
or too large to enter the microfluidic channel, hence not detected by single-molecule 
TCCD. The decrease in the calculated Q values were coincident with a reduction in 
the overall fluorescence signal measured as the total number of dye labels passing 
through the volume has decreased, further supporting insoluble fibril formation. 
A steady state population of soluble oligomers appeared in the aggregation of 
both unmodified and Ub-modified αS and did not change appreciably as the reaction 
proceeded over longer incubation times (Figure 3c). Only a fraction of aggregates is 
therefore able to form ThT-active aggregate species, where the formation of Ub-
modified αS aggregates is delayed compared to unmodified αS (shown in Figure 1c). 
The ThT assays further suggest that there could be more β-sheet content in the 
aggregates formed from unmodified αS, as bulky Ub moieties may obstruct close 
packing of Ub-αS aggregates. 
 
Proteasomes are able to target Ub-modified aggregates  
To study the degradation of Ub-modified amyloidogenic proteins, we purified 
proteasome holoenzyme from an established mammalian cell line[34] using an 
affinity column (SFigure 3a). The purified proteasome holoenzyme was resolved and 
validated by SDS-PAGE (SFigure 3b), transmission electron microscopy (TEM, 
SFigure 3c) and native gel electrophoresis in presence of an ATP-containing buffer 
(SFigure 3d). We could not quantitatively detect the presence of free proteasomal 
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Core Particles (CP) with Coomassie staining or under TEM. A batch of the yeast 
proteasome holoenzyme was used as reference for the detection of capped and 
uncapped CP under identical conditions (SFigure 3e). All four Dye-labeled tauK18 and 
αS protein constructs could be quantitatively degraded by the proteasome, confirming 
its activity (SFigure 4a and b). 
It has been reported that non-ubiquitinated aggregates resist degradation[11-
14], and that tau and αS oligomers have recently been shown to impede proteasome 
activity[17]. In addition, we recently demonstrated that the product of proteasome-
catalyzed fragmenting of tau and αS fibrils was small aggregate entities, supporting 
our previous report that proteasomes had no effect on soluble αS oligomers without 
ubiquitin modification[39]. We therefore tested whether N-terminal Ub modification 
on tau and αS oligomers would enable their disassembly by proteasomes. ThT was 
found to bind to the proteasome, which interfered with fluorescence measurements 
(SFigure 4c). Turning to single-molecule TCCD approach, we reproducibly detected 
a decrease in the level of soluble oligomers in both Ub-tauK18 and Ub-αS as late as 96 
hrs into the aggregation reaction (Table 1 shows a typical experiment). Ub-tauK18 
oligomers generated throughout the assembly process were largely removed after 
incubation in the presence of proteasomes (Table 1a). The effect was also significant 
for oligomers assembled from Ub-αS, which decreased in the presence of the 
proteasome (Table 1b).  
We previously used the relative fluorescence intensities of aggregates 
compared to monomers to calculate the apparent size of aggregates[31]. Analyzing 
the data in Table 1 revealed that the proteasome caused a general decrease in the 
aggregate level independently of the apparent aggregate size (STable 1), suggestive 
of gradual aggregate disassembly.  
Our previous work using the same confocal single-molecule technique found 
that the proteasome did not target oligomers that are not modified with Ub[11] and 
that these oligomers are not affected by active chaperones[35]. We therefore attribute 
the observed reduction in aggregate level specifically to the proteasome. No change in 
the proteasomal proteolytic or the ATP-dependent activity after incubation with Ub-
modified oligomers was observed (Figure 4a and b), consistent with observations 
after incubating proteasomes with fibrils[1]. 
The fibril-fragmenting activity of proteasome was shown to be independent of 
the peptidase activity[1]. To test whether the disassembly of Ub-modified aggregates 
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also did not rely on the proteasomal peptidase activity, we repeated the single-
molecule experiments using proteasomes that were pre-incubated with Velcade as 
before. The decrease in Ub-tauK18 or Ub-αS aggregates was not affected by Velcade-
mediated inhibition (Figure 4c and d), consistent with our recent observation[1].  
The ability of proteasomes to target Ub-modified oligomers was further 
resolved by Western blotting. Aggregates assembled from both Ub-tauK18 and Ub-αS 
were prone to proteasomal activity (SFigure 5a and c), while aggregates assembled 
from unmodified tauK18 and αS showed no detectable intensity change in the presence 
or absence of proteasome treatment (SFigure 5b and d). This is consistent with the 
hypothesis that aggregates formed from proteins N-terminally modified with Ub can 
be targeted by the proteasome while unmodified aggregates remain unchanged.  
 
Discussion 
Our current work has showed that the presence of an N-terminal Ub moiety on tauK18 
and αS results in distinct aggregation kinetics and aggregate conformations. 
Oligomers assembled from these Ub-modified proteins are prone to proteasomal 
activity. We previously demonstrated that proteasomes are able to target fibrils, as 
they are structurally distinct from non-filamentous aggregates. This study further 
complements our previous demonstration of proteasomal fibril-fragmenting 
activity[1] with an additional proteasomal ability to target Ub-modified oligomers. 
Intriguingly, size analysis of oligomers at various times of aggregation did not 
indicate any clear trends in their susceptibility to be removed by proteasomes (STable 
1), suggesting that the gradual disassembly of oligomers may not be a straightforward 
mechanism. 
As tight assembly and packing are key features of amyloid aggregates, 
presence of a Ub moiety at the N-terminus could potentially induce soluble oligomers 
into a conformation distinct from unmodified protein aggregates. In another of our 
previous work, we found that arachidonic acid could induce a conformational change 
in soluble αS oligomers that could subsequently be targeted by the proteasome[11], 
suggesting that the proteasome acted more effectively on modified than unmodified 
oligomers, which contained more compact structures.  
N-terminal monoubiquitination is associated with enzymes of the UFD 
pathway, which have been found in mammalian systems to target misfolded 
proteins[29,30] and foreign particles[36] for proteasomal degradation to prevent cell 
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stress. Our current study demonstrates that such N-terminally monoubiquitinated 
proteins may assemble into soluble oligomers, which are distinct to aggregates 
assembled from proteins ubiquitinated on Lys residues[25,26,37-39]. As 
demonstrated here, N-terminally modified oligomers may be efficient proteasomal 
targets that exist transiently in cells, and could therefore have escaped detection in 
traditional mass spectrometry analyses. The development of antibodies specific for N-
terminal mono-ubiquitination[36] and a dedicated mass spectrometry proteomics 
analysis[40], are likely to provide additional insights into this unique ubiquitination 
type.  
The complete monoUb modification on every protein within each oligomer in 
our study may provide avid recognition in vitro and enhance their disassembly 
efficacy at the proteasome. Physiologically, ubiquitination levels of tau and αS are 
likely to be dynamically regulated through both protein synthesis and degradation. 
Ubiquitin modifications on different positions within the proteins have distinct 
consequences for their aggregation properties. Our current study proves a novel 
principle of how N-terminal Ub-modification impedes aggregation, enables 
proteasomes to target oligomers and provides a possible option for oligomer 
disassembly by the ubiquitin-proteasome system. 
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Figure Legends 
 
Figure 1. Aggregation of N-terminally Ub-modified tau and α-synuclein (αS). (a) 
Full-length αS (containing at seven repeats) and the tetra-repeat domain (tauK18) of tau. 
Full-length tau (isoform 0N4R) is shown on top. (b) Ubiquitination of αS (left) and 
tauK18 (right) by UBE2W. UBE2W faithfully ubiquitinated tauK18 and αS after two 
hours incubation at 25°C, demonstrated by the shift in the band size. Results shown 
are representative of reactions independently repeated at least three times. (c-d) 
Aggregation of unmodified and Ub-modified tauK18 and αS, detected by Thioflavin T 
(ThT). (c) Ub-αS (blue) or αS (yellow) at 40 µM were aggregated under identical 
conditions with shaking at 37°C. (d) Ub-tauK18 (red) or tauK18 (green) at 10 µM 
aggregated under identical conditions, without shaking, at 37°C. Error bars represent 
standard deviation of independent triplicate measurements.  
 
Figure 2. Detection of aggregates by transmission electron microscopy (TEM). (a) 
Filamentous or amorphous aggregates assembled from αS (left) and Ub-αS (right) 
after 96 hrs of aggregation reaction. Arrows highlight positions of some typical 
aggregate structures. (b) Filamentous aggregates of tauK18 (left) and Ub-tauK18 (right) 
detected by TEM as in (a).  
 
Figure 3. Single-molecule fluorescence detection of tauK18 and αS aggregates. (a) 
Schematic representation of aggregation from N-terminally Ub-modified 
amyloidogenic proteins (in blue; Ub in yellow) tagged with Alexa488 (marine stars) 
and Alexa647 (red stars) in a 1:1 molar mixture. Monomeric proteins (left) carry a 
single fluorescent dye and cannot be detected using the coincidence criterion 
(Materials and Methods). Soluble oligomers (middle) will carry both dyes and 
satisfy the coincidence criterion. As aggregation progresses, fibrillar aggregates (in 
cyan; right) will form that may be insoluble or too large for detection. (b) 
Aggregation of tauK18 (left) or Ub-tauK18 (right) as detected by single-molecule 
measurements. The Q value is proportional to the percentage of oligomers. Error bars 
represent standard deviation of three independent measurements. (c) Aggregation of 
αS (left) or Ub-αS (right) detected by single-molecule measurements as in (b).  
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Table 1. Representative TCCD experiments of proteasomal degradation of (a) Ub-
tauK18 and (b) Ub-αS aggregates, respectively, illustrating how the single-molecule 
data were analyzed (see STable 1 for aggregate size dependency analysis). The 
experiments were performed in triplicate (see Figure 4 for average results of repeat 
experiments). At the indicated times after aggregation initiation (first column), the 
number of aggregates were counted after incubation with either the control buffer 
(second column) or with the proteasome (third column). The calculated percentage 
reduction of aggregates is shown (fourth column). 
 
Figure 4. Proteasome maintains its function in the presence of Ub-modified 
oligomers, which are disassembled independently of the proteolytic acitivity. (a) Ub-
tauK18 (top) or Ub-αS (bottom) aliquots from indicated aggregation times were 
incubated with the proteasome or with control buffer. After reaction completion, 
samples were resolved on a 3% native gel and visualized by LLVY-AMC 
fluorescence emission (λEx = 340 nm, λEm = 440 nm). A sample of the proteasome at 
the same concentration alone was used as control (ctrl). (b) Phosphate assay reporting 
the concentration of free phosphates after incubating proteasomes with Ub-modified 
oligomers for 20 hrs. Residual free phosphates were present in the ATP-containing 
buffer, but increased in presence of the proteasome. The free phosphate levels were 
not reduced when the proteasome was incubated with Ub-modified tauK18 or αS, 
suggesting that ATP hydrolysis was not affected. (c-d) Velcade does not affect 
aggregate removal by the proteasome. (c) Ub-tauK18 and (d) Ub-αS oligomers were 
assembled for 24 hrs (left) or 72 hrs (right) before mixing with the prepared 
proteasomes, incubated and subsequently measured by single-molecule TCCD. 
Proteasomes were pre-incubated with Velcade for 5 min before mixing with 
substrates. The percentage change in aggregate level is relative to the control sample 
without proteasome. Error bars represent standard error of mean from three sets of 
independent measurements.   
 
 
SFigure 1. Purification of Ub-tauK18 and Ub-αS. (a) Peak fractions of Ub-tauK18 
eluted from a typical run on gel filtration column were resolved on SDS-PAGE and 
proteins were stained with Coomassie blue. (b) Ub-αS samples were also purified and 
eluted from gel filtration column as in (a). The fractions collected and used for 
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experiments are underlined. Molecular weight markers are shown to the left of each 
gel. 
 
SFigure 2. Single-molecule confocal measurements of oligomers. (a) Dye-labeling 
scheme used for Ub-tauK18 and Ub-αS. The proteins were genetically engineered to 
carry a single Cys residue that enables covalent fluorescent dye labelling (see 
Materials and Methods). Each protein was labeled separately with Alexa488 or 
Alexa647 before mixing in a 1:1 molar ratio for subsequent aggregation. (b) Model 
representation of the single-molecule confocal instrument setup used. A multi-line 
laser source (iFLEX-Viper) with a modular single mode fibre delivery system was 
responsible for excitations at 488 nm and 640 nm. The two overlapping laser beams 
were focused using an objective with high numerical aperture into a microfluidic 
channel where a constant flow was applied to the protein sample (zoomed in). The 
sample was diluted to a concentration such that single molecules occupying the focal 
volume were simultaneously excited. Emitted fluorescence is captured using the same 
objective and separated from reflected excitation beam using a dichroic mirror (DRLP, 
dichroic long-pass filter). A second dichroic mirror splits the emission light beam 
again for detection in two separate APDs (avalanche photodiode detector). ALP (anti-
light pollution) filters and AF (band pass) filters used are indicated.  
 
SFigure 3. Purification of 26S proteasome holoenzyme from a HEK293-derived cell 
line. (a) Molecular representation of the proteasome holoenzyme (pdb-id 5GJQ). The 
20S core particle (CP, grey) is capped at both ends with 19S regulatory particles (RP, 
teal). Rpn11 (magenta), a deubiquitinase, is the subunit tagged for affinity purification 
of the proteasome (see Materials and Methods). (b) The presence of the individual 
proteasomal subunits was detected by SDS-PAGE after purification. (c) A typical 
batch of proteasome holoenzyme visualized by TEM. The CP and RPs are highlighted. 
(d) Purified proteasome holoenzymes used in this study resolved by native gel 
electrophoresis and detected under UV with LLVY-AMC (left) or Coomassie-stained 
(right) (e) A batch of yeast 26S proteasomes detected under UV (left) or stained with 
Coomassie (right). 
 
SFigure 4. Studying proteasome activities on N-terminally Ub-modified proteins. (a) 
Dye-labeled αS (top) and Ub-αS (bottom) monomers can be degraded by the 
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proteasome over time. Samples were resolved by SDS-PAGE and fluorescence 
emission was detected on a Typhoon Imager. A lower molecular weight degradation 
fragment developed over time beneath the substrate bands. (b) Degradation of dye-
labeled tauK18 (top) and Ub-tauK18 (bottom) monomers, performed and visualized as in 
(a). (c) ThT can bind to the proteasome. The proteasome incubated at 0, 40, or 120 
nM with ThT at 10 µM final concentration. Samples were excited at 415 nm and 
fluorescence emission was detected from 460 to 560 nm. 
 
SFigure 5. Degradation assays of Ub-modified oligomers. Degraded samples were 
resolved by SDS-PAGE. Oligomers assembled from (a) Ub-tauK18 or (b) tauK18 were 
incubated with the proteasome or the control buffer, resolved by SDS-PAGE and 
transferred to a PVDF membrane for Western blot detection at high (top) and normal 
exposure (bottom) to detect changes in the oligomer or monomer bands. Oligomers 
assembled from (c) Ub-αS or (d) αS were subjected to proteasomal degradation and 
presented as in (a and b). Note that the proteasome alone did not contribute to any 
bands detected by either anti-tau or anti-αS antibodies. The reduction in oligomer 
bands of Ub-tauK18 and Ub-αS aggregates throughout the aggregation process was not 
an effect of the reducing agent or other factors because samples in control lanes and 
proteasome-containing lanes underwent the same procedure and were kept in the 
same buffer. Each assay was independently repeated at least three times.  
 
Supplementary Table 1. Changes in oligomer size distribution following 
proteasomal degradation calculated from data in Table 1. (a) Ub-tauK18 and (b) Ub-
synuclein oligomers are grouped according to their apparent oligomer sizes into 
‘Small’ (15mers or smaller), ‘Medium’ (between 15mers and 30mers), and ‘Large’ 
(between 31mers and 45mers).  
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Material and Methods 
 
Molecular biology of plasmids for protein expression 
A single Ub moiety was expressed in tandem to the proteins of interest (tauK18 or αS). 
The DNA sequence of Ub was introduced either at the 5’ end, immediately before the 
ATG codon, or at the 3’ end, after the last translated codon of the open reading frame. 
When the Ub coding sequence was cloned upstream of the wild-type αS or tauK18 
coding sequences, a mutation corresponding to Gly to Ser was introduced at residue 
76, the last residue of Ub. The constructs were subsequently sub-cloned into a 
pOPINF vector using restriction enzymes, resulting in a His6-tag at the N-terminus of 
the Ub. TauK18 or αS sequences were also separately cloned into the pOPINF vector 
without the Ub sequence, so that the His6-tag is immediately N-terminal to the 
substrate.  
Cys mutations were introduced using site-directed mutagenesis on Ala90 of 
αS or Ile202 of tau (annotation based on the 0N4R isoform sequence). We previously 
showed that introduction of Cys and subsequent dye-labeling did not disrupt the 
integrity and aggregation properties of these proteins[31,32]. Equivalent mutations 
were separately introduced into Ub-αS and Ub-tauK18 constructs. The two other Cys 
residues in wild-type tauK18 sequence were mutated to Ala[32].  
The full-length sequence of mouse E1 in pET28a vector (kind gift from David 
Komander) and human UBE2W in pET15b vector (kind gift from Wade Harper, 
Addgene plasmid #15809) were coded to include an N-terminal His6-tag to facilitate 
protein expression. Plasmids for protein expression of full-length αS in pT7-7 vector 
or tauK18 sequence in pJExpress vector (custom designed) alone coded for untagged 
constructs of the wild-type sequence of human αS or tauK18. These untagged 
constructs coded for wild-type sequences of the N-terminal residues used in the 
ubiquitination by UBE2W. 
 
Recombinant protein purification 
Plasmids were transformed into Rosetta2 (DE3) pLysS cells (Novagen) and grown in 
LB media to OD600 = 1.0 before overnight induction with 1 mM IPTG at 20°C. Cells 
were collected the next day by centrifugation at 5000 × g for 30 min before lysis by 
sonication. The cell lysate was cleared by centrifugation at 21000 × g for 30 min at 
4°C.  
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The supernatant from purification of His6-tagged proteins was loaded onto a 
self-packed cobalt column (Clontech). Unbound proteins were washed off with 
Loading Buffer (50 mM Tris-HCl [pH 7.4], 100 mM NaCl, 10 mM imidazole), and 
bound proteins subsequently eluted with Elution Buffer (50 mM Tris-HCl, 100 mM 
NaCl, 200 mM imidazole, pH adjusted to 7.4).  
Preparation of the supernatant from purification of untagged αS and tauK18 
followed established protocols (e.g. [31,41]). In brief, the cleared supernatant was 
poured into a 50 ml falcon tube and incubated in boiling water for 10 min before 
cooling down to room temperature. The solution was cleared with a second 
centrifugation step at 21000 × g for 30 min at 4°C and the supernatant filtered before 
further purification.  
The eluted or filtered samples were further purified using ion exchange (IEX) 
chromatography columns HiTrapQ (for αS constructs) or HiTrapS (for tau 
constructs), running a linear NaCl gradient from Buffer A (50 mM Tris-HCl [pH 7.4], 
50 mM NaCl) up to 1 M NaCl.  
Peak fractions from the IEX were concentrated to < 4 ml and loaded onto a 
Superdex 16/60 gel filtration column (GE Healthcare) in Buffer A. Eluted fractions 
were separated by SDS-PAGE and fractions judged to be >99% pure by Coomassie 
stain were further concentrated and flash frozen in aliquots (SFigure 1). Protein 
concentrations were measured on a NanoDrop.  
 
Dye-labeling on proteins 
Proteins carrying Cys substitutions were dialyzed into Labeling Buffer (50 mM Tris-
HCl [pH 7.2]) before dye labeling. AlexaFluor 488 C5 maleimide or AlexaFluor 647 
C2 maleimide (Invitrogen) were dissolved in DMSO and added to the proteins in a 
1:1.2 molar ratio of excess dye. We routinely use this protocol to ensure that 
essentially all proteins are labeled as detected by ion exchange chromatography, size 
exclusion chromatography, and mass spectroscopy. The labeling reaction was 
quenched after 1 hr with fresh DTT at 100 mM final concentration and loaded onto a 
HiPrep 26/10 desalting column (GE Healthcare). The final labeled proteins were 
concentrated to at least 80 µM and flash-frozen in Protein Buffer (50 mM Tris-HCl 
[pH 7.2], 50 mM NaCl, 0.01% Tween20) in small aliquots. Concentrations were 
determined by NanoDrop. 
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Purification of mammalian proteasomes 
Proteasomes were purified from a HEK293T cell line stably expressing a Rpn11-
TEV-Biotin tag (kind gift of Lan Huang, UC Irvine) using established protocols[34]. 
Briefly, cells were grown to 100% confluence and collected with a scraper before 
resuspension in ice-cold Proteasome Buffer (50 mM Tris [pH 7.5], 0.5% NP-40, 10% 
glycerol, 5 mM ATP, 1 mM DTT, 5 mM MgCl2,). A Dounce homogenizer was then 
used to lyse the cells and the lysate was cleared by centrifugation at 3000 × g for 5 
min at 4°C. The lysate was incubated overnight at 4°C in 2-ml bed volume of pre-
equilibrated NeutrAvidin resin beads (Pierce). Unbound proteins were washed off 
with Proteasome Buffer. Proteasome was subsequently released from the column with 
TEV protease (Invitrogen) at 30°C and concentrated to > 2 µM before flash-freezing.  
 
UBE2W ubiquitination assays 
Ubiquitination assays were carried out at 25°C in Ubiquitination Buffer (50 mM Tris 
[pH 7.5], 10 mM ATP, 1 mM DTT, 10 mM MgCl2,), containing 0.5 µM of E1, 1 µM 
of UBE2W, 200 of µM wild-type Ub (Sigma) and 10 µM of untagged αS or tauK18 
substrate. The reactions were incubated for 2 hrs before quenching by Laemmli 
Buffer. Substrates were excluded in control samples to test for cross-reactivity of the 
antibodies used with the ubiquitinating enzymes or the Ub (Figure 1b). 
 
Protein aggregation assays 
For protein aggregation, Ub-tauK18 or tauK18 were diluted in PBS Buffer (MP 
Biomedicals) containing 0.01% sodium azide to 10 µM final concentration and 
incubated at 37°C. An equimolar amount of heparin (H3393, Sigma-Aldrich) was 
added to initiate tauK18 aggregation reactions. Aggregation assays for Ub-αS or αS 
were performed at 40 µM final protein concentration in PBS Buffer containing 0.01% 
sodium azide and incubated at 37°C shaking, as described[31]. We did not detect 
pellets of insoluble fibrils after 10 min centrifugation at 13000 × g for Ub-tauK18 or 
Ub-αS aggregates.  
 
Thioflavin T fluorescence assays 
Thioflavin T (Sigma) was dissolved in PBS and filtered through a 0.02 µm filter. The 
concentration was determined by UV absorbance at 405 nm on a NanoDrop. Aliquots 
were removed from tauK18 (10 µl) or αS (5 µl) samples at indicated times after 
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aggregation initiation and mixed with 40 µl of the ThT solution at 10 µM. The 
mixture was incubated for 10 min and subsequently measured on a spectrophotometer 
(λEx = 415 nm, Varian Eclipse). Integral area between 460 and 560 nm of the emission 
spectrum was calculated for each time point. The mean value of triplicate aggregation 
assays was used to plot Figure 1c and d. Each dataset was fitted to a sigmoidal 
function, defined as 
 
             
 
    
                              
 
where t is the time after aggregation initiation in hrs and IntensityThT is the mean 
integral area of fluorescence emission. All plots were calculated and generated using 
IgorPro (Wavemetrics). The sigmoidal behavior of aggregation produces the time, 
thalf, needed for IntensityThT to reach 50% of the maximal plateau value.  
 
Degradation assays 
Degradation assays were typically performed at 25°C in Degradation Buffer (50 mM 
Tris-HCl [pH 7.5], 10 mM ATP-MgCl2, 30 mM creatine phosphate, 4 µM creatine 
kinase) containing 40 nM proteasome. Control samples were set up in the same buffer 
without adding the proteasome. TauK18 substrates were reacted for 3 hrs at a final 
concentration of 2.6 µM in PAGE-based assays and 0.2 µM in single-molecule 
assays. Incubation time for αS samples was 12 hrs and diluted to a final concentration 
of 10 µM in PAGE-based assays and 1 µM in single-molecule assays. We 
occasionally observe secondary dimer or higher bands emerging with prolonged 
incubation when the substrate concentration is higher than 10 µM, indicating sporadic 
aggregation during degradation assays. For the inhibitor assays, the proteasome was 
pre-incubated for 5 min at 25°C with Velcade (ProteasomeVelcade) to a final 
concentration of 100 µM.    
 
Resolving of aggregate samples by gel electrophoresis and Western blotting 
Proteasomes used in the overnight degradation assays were resolved on self-poured 
3% polyacrylamide native gels and detected with a fluorogenic model substrate, 
LLVY-AMC, as described previously[42]. For Western blotting, protein samples 
were first separated on 4-12% NuPAGE gels (Invitrogen) and then transferred to 
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PVDF membranes as per manufacturer’s protocol (Mini Trans-Blot wet transfer, 
Biorad). Samples taken were quenched with Lammeli buffer but not heated (to 
preserve the oligomeric bands). Mouse anti-tau (1E1/A6, Merck) or rabbit anti-αS 
(ab138501, Abcam) were used as primary antibodies following standard Western 
blotting methods. Secondary anti-mouse and anti-rabbit antibodies compatible with 
detection on an Odyssey CLx Imager or a Typhoon scanner were purchased from Li-
Cor or Invitrogen. 
 
Colorimetric phosphate assay 
ATPase kit containing malachite green and ammonium molybdate was purchased 
from Abcam (ab65622). For assays in Figure 4b, 40 µl of each reaction (set up as 
described in Degradation assays section) was mixed with 6 µl of the malachite green 
reagent and incubated for 15 min before measurement. The colorimetric output was 
measured at OD = 650 nm on a microplate reader. A linear standard curve from 0 to 
20 mM of free phosphates was established to convert colorimetric reading into 
phosphate concentration. Three independent replicate experiments were performed for 
each reaction. 
 
Transmission electron microscopy imaging 
Samples shown in Figure 2 were aggregated beyond 96 hrs and applied onto a 
carbon-coated 400 mesh copper grid (Agar Scientific). Mammalian proteasome was 
applied at 100 nM concentration. The grids were then washed with double distilled 
water and stained with 2% (w/v) uranyl acetate for 1 min. TEM images were acquired 
using Tecnai G2 microscope (13218, EDAX, AMETEK) operating at an excitation 
voltage of 200 kV.  
Single-molecule measurements 
The instrument setup and collection of single-molecule data are based on our earlier 
works and have been extensively described (e.g. references [31,43]). Briefly, single-
molecule data were collected on a custom-built system using overlapping lasers with 
excitation maxima at 485 nm and 640 nm (see SFigure 2a). The rate of modulation 
for both lasers was at 10 modulations per millisecond. Samples were measured under 
flow using custom-made PDMS microfluidics devices following published 
procedures[45]. Aggregates were assembled from protein monomers labeled with 
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either AlexaFluor 488 or AlexaFluor 647 and mixed in a 1:1 molar ratio for 
aggregation (SFigure 2a). This ensures that only aggregates will carry both dyes and 
will be detected by the coincidence criterion[33].  
Degradation assays were performed for 3 hrs (Ub-tauK18) or 12 hrs (Ub-αS) 
and diluted for immediate single-molecule measurement. Fluorescent protein samples 
were diluted to 100 pM (Ub-αS) or 40 pM (Ub-tauK18) final concentration and 
measured under flow according to previously established methods[32,44]. The bin 
time and flow rates for Ub-αS and Ub-tauK18 constructs were individually optimized 
to achieve the highest value of Q as described previously[11,32]. Ub-αS aggregates 
were measured at 100 µl/hr flow rate and the fluorescence signals were collected with 
0.1 ms bin time. For Ub-tauK18 samples the flow rate and bin time were 50 µl/hr and 
0.2 ms, respectively. Data were typically collected for 15 min at 25°C in frames of 
50,000 bins. Independent triplicate experiments were performed for Ub-tauK18 and 
Ub-αS aggregation reactions. A representative set of aggregate degradation 
measurements is shown in Table 1.  
 
Single-molecule data analysis 
We used the AND criterion to detect coincidence events in the two channels[33]. This 
separates aggregation events from background monomers by accepting only those 
signals for which the blue- and the red-excited channels are above the threshold value. 
The proportion of monomers that are associated to form oligomers is expressed using 
the association quotient Q, which is defined as 
 
  
     
           
                         
 
where A and B are the rates of detection of events in the two fluorescent channels, 
respectively, and C is the detection rate of coincident events; τ is the interval time of 
detection so that the ABτ expresses the coincident events that occur by chance[33]. 
We also measured the level of background detection of the buffer containing no 
fluorescent proteins and applied a uniform threshold five-fold over the background in 
both red- and blue-detector channels (10 kHz) to remove noise signals. We found, in a 
previous work using this method, good agreement between size distribution of 
particles immobilized onto a surface and those measured in solution of the same 
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particles[44], showing that potential laser beam inhomogeneity will not become a 
significant effect in these experiments. A reference duplex DNA sample of 40 base 
pairs labeled with AlexaFluor 488 and AlexaFluor 647 at the 5’ end of each of the 
single DNA strands, repeatedly gave a Q value of 30%, using the same analysis[43].  
Each single-molecule measurement was normalized to a standard number of 
frames and the number of significant coincident events was counted. The percentage 
decrease in oligomers upon proteasome treatment is calculated as follows: 
 
 
         
                           
             
       
 
expressed in percentage. The estimation of apparent aggregate size was carried out as 
previously described[31], based on the fluorescence intensities of each aggregate as it 
passed through the probe volume. In brief, the approximate monomer number per 
aggregate can be extracted assuming that 50% of monomers are donors using the 
equation 
 
                  
        
          
             
 
where IDA represents the donor fluorescence intensity in presence of acceptor, IA the 
acceptor fluorescence intensity. ID_monomer corresponds to the average intensity of 
donor monomers, and γ to a correction factor that accounts for different quantum 
yields and detection efficiencies of the donor and acceptor.  
Previous control experiments on DS aggregates showed that this analysis 
recovered the same apparent size distribution as that measured when the aggregates 
were immobilized on a glass surface[44]. Depending on the calculated apparent 
aggregate size, each aggregate was subsequently arbitrarily classified either as Small 
(size ≤ 15), Medium (size 16-30) or Large (size 31-45), and the frequency of each 
group reported as in STable 1. Aggregate size beyond Large was not detected in our 
measurements.
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